Question to the Board. The problem with a “one

Question to the Board. The problem with a “one size fits all” vaccine is that the human condition is vastly diverse. Between the basic genetics, medical pre-conditions and age factors, the hardest part of an effective vaccine besides maximizing the efficacy, is controlling the adverse side effects. With the Ii-key technology how hard do you think it would be to create a series of “designer” vaccines specifically targeting the Covid virus but designed for minimum side effects for a specific type of the human population (age, genetics, medical conditions)? Could these vaccine variations be run concurrently as a single trial? Would this be economically feasible? Since this would be a first ever trial type, how would the FDA weigh in? If this would be possible, then that would make NGIO the creator of the ultimate “complete vaccine” Just ruminating, still any thoughts out there?